242 related articles for article (PubMed ID: 35227453)
1. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
Alarid-Escudero F; Schrag D; Kuntz KM
Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
Ayvaci MU; Shi J; Alagoz O; Lubner SJ
Med Decis Making; 2013 May; 33(4):521-32. PubMed ID: 23313932
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
[TBL] [Abstract][Full Text] [Related]
6. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
8. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.
Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
Pharmacoeconomics; 2014 Oct; 32(10):1005-13. PubMed ID: 24920195
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
[TBL] [Abstract][Full Text] [Related]
12. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
Koperna T; Semmler D
Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
15. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
16. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
[TBL] [Abstract][Full Text] [Related]
17. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Wu B; Li T; Cai J; Xu Y; Zhao G
BMC Cancer; 2014 Dec; 14():984. PubMed ID: 25526802
[TBL] [Abstract][Full Text] [Related]
19. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
Monz BU; König HH; Leidl R; Staib L; Link KH
Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]